The blue triangles represent P values for the association when we restricted the control group to men with low PSA (<0.5 ng/ml), and the red circles represent P values for the association when we did not restrict the control group to men with low PSA. and rs2735839) , located in the 3′ untranslated region of KLK3 and in high linkage disequilibrium (LD; r 2 = 0.8; Fig. 1) , along with four variants 8-23 kb upstream of the gene (rs2659056, rs2569729, rs266849 and rs266870) and several variants about 7 kb downstream (rs1506684 and rs2569739, in high LD, r 2 = 1.0), were strongly associated with serum PSA concentrations (for example, rs2735839, P trend = 4.1 × 10 −9 ; Table 1 and Fig. 1a) ; however, only rs2735839 remained significantly associated with PSA concentration (P = 0.0041) when all these SNPs were simultaneously included in the multivariate model.
Eeles et al. 1 reported strong associations between three SNPs in KLK3 and prostate cancer in a stage 1 GWAS (P values were 1.2 × 10 −7 , 1.0 × 10 −16 and 2.4 × 10 −20 for rs2659056, rs266849 and rs2735839, respectively), where controls were selected by design for low PSA (<0.5 ng/ml) and no limitations were placed on case-group PSA values. By contrast, the stage 2 replications in non-PSA selected groups in this study showed attenuated risk estimates and P values (P values were 0.424, 0.228 and 0.0002, respectively), largely due to differences between stage 1 and stage 2 control subject minor allele frequencies. Pal et al. 2 reported a strong association of prostate cancer with KLK3 variants, where control subjects were also preferentially selected by PSA level (<2.5 ng/ml).
When, as an exercise, we preferentially limited the men in the control group in the PLCO Trial GWAS to those with PSA <0.5 ng/ml, prostate cancer risk associations (Fig.  1b and Supplementary Table 3 online) were greater by more than fivefold for some genotypes, even though the same SNPs showed no clear association when the full control group was used (Fig. 1b and Table 1 ). Furthermore, modest KLK3 associations with prostate cancer risk observed in our full case-control series and in other studies where controls are not selected by design based on PSA 3 may still be related to PSA-based case ascertainment, because PSA is widely used as a clinical aid in selecting men for biopsy for suspect prostate cancer. KLK SNPs were not associated with prostate cancer risk in PLCO when only cases and controls with high PSA levels or only cases and controls with low PSA levels were compared (Supplementary Table   4 online). Thus, the observed associations between the KLK SNPs and prostate cancer risk in earlier studies [3] [4] [5] and in our exercise in PLCO may be due to selection for PSA differentials rather than to a causal relationship with disease risk.
PSA is a serine protease functioning in the liquefaction of seminal coagulum 7 . Consistent with our data, Pal et al. 2 showed serum PSA associations with rs266849 and rs1058205, and Cramer et al. 4 showed that rs925013 and rs2739448 in the 5′ region of KLK3 are related to increased KLK3 promoter activity and serum PSA level. In the present study, the association with PSA was strongest with rs2735839, which is highly correlated with rs1058205 (r 2 = 0.8). The associations observed with the other SNPs in our study seemed to be largely driven by their linkage disequilibrium with rs2735839. Sliding window haplotype analysis ( Supplementary  Fig. 1 online) and close inspection of the most strongly associated haplotype window (Supplementary Table 5 online) suggested that additional unmeasured risk variants may also influence PSA concentrations.
PSA is an early marker for the presence of prostate cancer, and it has contributed to the near doubling of diagnosed cases over the past two decades in countries where its use is common 8 . Trials are underway to determine whether screening with PSA reduces prostate cancer mortality 5, 9 . Although not related to risk in our study, KLK3 variant status was related to PSA-test positivity in PLCO control men (Supplementary Table 6 online), and a combination of KLK3 genotype and serum PSA evaluation, possibly also including other protein and DNA tests 10 , may lead to improvements in protocols for the early detection of prostate cancer.
In conclusion, SNPs in the KLK3 region were not associated with prostate cancer risk in our series of five case-control studies. Furthermore, with widespread use of PSA in clinical practice, even modest associations observed between KLK3 SNPs and prostate cancer risk in some epidemiologic studies may be due to PSA-directed differential identification of prostate cancer cases with particular KLK3-PSA profiles.
